425: ReShape Lifesciences to Merge with Vyome Therapeutics, Sells Assets to Biorad Medisys

ReShape Lifesciences is set to merge with Vyome Therapeutics in an all-stock transaction while simultaneously selling its assets to Biorad Medisys for $5.16 million.

Summary

• ReShape Lifesciences and Vyome Therapeutics have entered into a definitive merger agreement for an all-stock transaction.
• Upon closing, ReShape will be renamed Vyome Holdings, Inc. and is expected to trade under the Nasdaq ticker symbol 'HIND'.
• Existing ReShape stockholders will own approximately 11.1% of the combined company, subject to net cash adjustments at closing.
• ReShape has also entered into an asset purchase agreement with Biorad Medisys to sell substantially all of its assets, including the Lap-Band System, Obalon Gastric Balloon System, and the Diabetes Bloc-Stim Neuromodulation (DBSN) System, for $5.16 million in cash, subject to adjustments.
• Accredited investors have committed to purchase a minimum of $7.3 million in securities of ReShape, Vyome and Vyome's subsidiary.
• Series C preferred stockholders have agreed to reduce their liquidation preference from $26.2 million to the greater of (i) $1 million, (ii) 20% of the asset sale purchase price, and (iii) the excess of ReShapes actual net cash over the minimum required at closing.
• The merger and asset sale are subject to customary closing conditions, including stockholder approval, SEC effectiveness of the registration statement, and Nasdaq approval of the continued listing of the combined company.

Sentiment

Score: 6

Explanation: The announcement is a mix of positive and negative elements. The merger provides potential future value, but the asset sale and reduced liquidation preference are negative for current ReShape stakeholders. The sentiment is neutral overall.

Positives

• The merger with Vyome is expected to provide ReShape stockholders with the potential to benefit from the combined company's prospects.
• The asset sale to Biorad Medisys provides ReShape with $5.16 million in cash, which will contribute to the net cash calculation for the merger.
• The commitment from accredited investors to purchase a minimum of $7.3 million in securities provides additional capital for the combined company.
• The reduction in the series C preferred stock liquidation preference facilitates the merger and allows common stockholders to recognize potential value.

Negatives

• Existing ReShape stockholders will own a minority stake (approximately 11.1%) in the combined company.
• The asset sale means ReShape will no longer own its existing product lines, including the Lap-Band and Obalon systems.
• The series C preferred stockholders are taking a significant reduction in their liquidation preference.

Risks

• The merger is subject to customary closing conditions, including stockholder approval, SEC effectiveness of the registration statement, and Nasdaq approval.
• There is a risk that the merger or asset sale may involve unexpected costs, liabilities, or delays.
• ReShapes business may suffer as a result of uncertainty surrounding the merger and asset sale.
• The outcome of any legal proceedings related to the merger or asset sale is uncertain.
• ReShape may be adversely affected by other economic, business, and/or competitive factors.

Future Outlook

The combined company will focus on advancing the development of its immuno-inflammatory assets and on identifying additional opportunities between the world-class Indian innovation corridor and the U.S. market.

Management Comments

• Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, stated that the merger and asset sale maximize stockholder value.
• Krishna K. Gupta, current Director of Vyome and to be appointed Chairman of the combined company, stated that they are positioning Vyome for success in the public markets and intend to continue addressing the unmet needs of patients suffering from immuno-inflammatory diseases.
• Venkat Nelabhotla, President & Chief Executive Officer of Vyome, stated that they are confident in their ability to potentially build significant value with their pipeline of novel local agent drugs.

Industry Context

The merger reflects a trend of pharmaceutical companies combining to leverage pipelines and expertise, particularly in specialized therapeutic areas like immuno-inflammatory diseases. The asset sale allows ReShape to focus on the merger while monetizing its existing assets.

Comparison to Industry Standards

• Comparable companies in the pharmaceutical sector often engage in mergers and acquisitions to expand their product portfolios and pipelines.
• The all-stock transaction is a common structure for mergers, particularly when one company is smaller or has limited cash resources.
• The asset sale is similar to other instances where companies divest non-core assets to focus on strategic priorities.

Management Changes

Stakeholder Impact

• ReShape stockholders will receive shares in the combined company, with potential for future value creation.
• ReShape employees may be affected by the asset sale and merger, with potential for job losses or changes in roles.
• Vyome stockholders will gain access to the public markets and potential for increased liquidity.
• Customers of ReShape will see changes in product ownership and potentially new product offerings from the combined company.

Next Steps

• ReShape will file a joint proxy statement/prospectus with the SEC.
• ReShape will seek stockholder approval for the merger and asset sale.
• The companies will work to satisfy the closing conditions, including Nasdaq approval.
• The merger and asset sale are expected to close upon satisfaction of all conditions.

Key Dates

Keywords

Merger, Acquisition, ReShape Lifesciences, Vyome Therapeutics, Biorad Medisys, Asset Sale, Liquidation Preference, Stockholders, Net Cash, All-Stock Transaction